CertaraCERT +2.88%65 EV-to-EBITDA is 13.62 as of Jul. 13, 2026, which is 62% below its 10-year median of 35.51. GuruFocus rates CERT with a GF Score™ of 65/100 and a GF Value™ of $13.37 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 505 Healthcare Providers & Services companies, Certara ranks worse than 58.22% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Certara's enterprise value is $1,234.3 Mil.
Certara's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $90.6 Mil. Therefore, Certara's EV-to-EBITDA for today is 13.62.
The historical rank and industry rank for Certara's EV-to-EBITDA or its related term are showing as below:
CERT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7167.51 Med: 35.51 Max: 1844.98
Current: 13.62
During the past 8 years, the highest EV-to-EBITDA of Certara was 1844.98. The lowest was -7167.51. And the median was 35.51.
CERT's EV-to-EBITDA is ranked worse than 58.22% of 505
companies
in the Healthcare Providers & Services industry
Industry Median: 11
vs CERT: 13.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-13), Certara's stock price is $6.965.
Certara's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.100. Therefore, Certara's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Certara (NAS:CERT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Certara's share price for today is $6.965.
Certara's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.100.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Certara's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Certara's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Certara EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Certara's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Certara's EV-to-EBITDA falls into.
Certara's current Enterprise Value is $1,234.3 Mil.
Certara's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $90.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Certara (CERT) has a EV-to-EBITDA of 13.62 as of Jul. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Certara. This is 62% below median its historical median of 35.51. According to the industry distribution chart, Certara ranks #294 out of 505 companies in the Healthcare Providers & Services industry, placing it in the top 58.2%.
Is Certara's EV-to-EBITDA too high?
Certara's current EV-to-EBITDA of 13.62 is 62% below median its 10-year median of 35.51. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.00. Certara's value of 13.62 is 23.8% above this industry median. Based on the distribution chart, Certara ranks #294 out of 505 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Certara has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Certara's EV-to-EBITDA compare to TALK and GDRX?
According to the Healthcare Providers & Services industry distribution chart, Certara ranks #294 out of 505 companies for EV-to-EBITDA. This places Certara in the lower half of its industry. The industry median EV-to-EBITDA is 11.00. Certara's value of 13.62 is 23.8% above this benchmark. While the company's 10-year median is 35.51 vs. the industry median of 11.00, Certara has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.00, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Certara's current EV-to-EBITDA of 13.62 is 23.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Certara. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Certara's current EV-to-EBITDA is 13.62, which is 62% below median its own 10-year median of 35.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Certara stock overvalued right now?
Based on GuruFocus' analysis, Certara (CERT) is currently considered Possible Value Trap. The stock's GF Value™ is $13.37, compared to a current price of $6.97 — trading 47.9% below its estimated fair value. The current EV-to-EBITDA is 13.62, which is 62% below median its 10-year median of 35.51 and 23.8% above the Healthcare Providers & Services industry median of 11.00. Certara's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Certara (CERT), the current EV-to-EBITDA is 13.62 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Certara (CERT) Overvalued in 2026?
Based on GuruFocus' analysis, Certara stock appears to be undervalued.
The current stock price of $6.97 is trading 47.9% below its estimated GF Value™ of $13.37.
GuruFocus considers Certara to be Possible Value Trap.
Key valuation signals for CERT:
EV-to-EBITDA: 13.62 (62% below median its 10-year median of 35.51)
GF Value™: $13.37 vs. price of $6.97 (47.9% below fair value)
Industry Position: 23.8% above the Healthcare Providers & Services median (#294 of 505)
No single metric tells the full story. See the CERT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
65GF Score
Get the complete analysis for CERT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERT has been successfully added to your 
